Quick Answer
Aptose Biosciences Inc. reported Net Income of -$25.47 million for fiscal year 2025.
Aptose Biosciences Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$25.47M -0.1% |
-$25.43M +50.3% |
-$51.21M -22.4% |
-$41.82M +36.0% |
-$65.35M -18.3% |
-$55.24M -110.2% |
| Diluted EPS | -$10.41 +71.4% |
-$36.38 +84.0% |
-$227.43 -3244.6% |
-$6.80 -831.5% |
-$0.73 | — |
| Total Assets | $10.01M -1.1% |
$10.13M -22.0% |
$12.99M -74.5% |
$51.03M -38.2% |
$82.53M -34.6% |
$126.26M +25.7% |
| Cash and Equivalents | $935.0K -84.8% |
$6.15M -33.5% |
$9.25M -75.0% |
$36.97M -5.5% |
$39.11M -66.7% |
$117.39M +47.0% |
| Stockholders Equity | -$27.17M -498.0% |
-$4.54M -56.6% |
-$2.90M -107.7% |
$37.74M -49.2% |
$74.24M -37.6% |
$118.92M +26.6% |
| R&D Expense | $11.34M -24.9% |
$15.10M -54.6% |
$33.27M +35.6% |
$24.53M -46.7% |
$45.98M +57.0% |
$29.29M +74.0% |
| Shares Outstanding | 2.55M +27.2% |
2.01M +657.7% |
264,745 -95.7% |
6.16M -93.3% |
92.22M +3.8% |
88.88M +16.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$5.12M | +26.3% | +27.3% |
| Diluted EPS | September 30, 2025 | -$2.01 | +82.3% | +27.2% |
| Total Assets | September 30, 2025 | $6.34M | -42.0% | +13.4% |
| Cash and Equivalents | September 30, 2025 | $613.0K | -92.3% | +10.8% |
| Stockholders Equity | September 30, 2025 | -$19.45M | -112.9% | -35.3% |
| R&D Expense | September 30, 2025 | $2.21M | -53.1% | -33.1% |
| Shares Outstanding | September 30, 2025 | 2.55M | -86.9% | +0.0% |
- Aptose Biosciences Inc. reported Net Income of -$25.47 million for fiscal year 2025.
- Aptose Biosciences Inc. showed a decrease of -0.1% in Net Income compared to the prior fiscal year.
- Aptose Biosciences Inc. reported Diluted EPS of $10.41 per share (loss) for fiscal year 2025.
- Aptose Biosciences Inc. showed an increase of +71.4% in Diluted EPS compared to the prior fiscal year.
- Aptose Biosciences Inc. reported Total Assets of $10.01 million for fiscal year 2025.
- Aptose Biosciences Inc. showed a decrease of -1.1% in Total Assets compared to the prior fiscal year.
- Aptose Biosciences Inc. reported Cash and Equivalents of $935.0 thousand for fiscal year 2025.
- Aptose Biosciences Inc. showed a decrease of -84.8% in Cash and Equivalents compared to the prior fiscal year.
- Aptose Biosciences Inc. reported Stockholders Equity of -$27.17 million for fiscal year 2025.
- Aptose Biosciences Inc. showed a decrease of -498.0% in Stockholders Equity compared to the prior fiscal year.
- Aptose Biosciences Inc. reported R&D Expense of $11.34 million for fiscal year 2025.
- Aptose Biosciences Inc. showed a decrease of -24.9% in R&D Expense compared to the prior fiscal year.
- Aptose Biosciences Inc. reported Shares Outstanding of 2.55 million shares for fiscal year 2025.
- Aptose Biosciences Inc. showed an increase of +27.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: